Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in December 2018 at the end of the 10-year period of market exclusivity.
On 6 February 2002, orphan designation (EU/3/01/084) was granted by the European Commission to Pharmion Limited, United Kingdom, for azacitidine for the treatment of myelodysplastic syndromes.
The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in October 2008.
Azacitidine in treatment of myelodysplastic syndromes has been authorised in the EU as Vidaza since 17 December 2008.
The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in June 2018.
Treatment of myelodysplastic syndromes
|Orphan designation status||
|EU designation number||
|Date of designation||
Celgene Europe B.V.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: